These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 20062935)

  • 1. High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis.
    Kerr J; Linkins LA
    Thromb Haemost; 2010 Jan; 103(1):123-8. PubMed ID: 20062935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients.
    Dahl OE; Gudmundsen TE; Bjørnarå BT; Solheim DM
    Acta Orthop Scand; 2003 Jun; 74(3):299-304. PubMed ID: 12899550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
    Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
    Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
    Wåhlander K; Larson G; Lindahl TL; Andersson C; Frison L; Gustafsson D; Bylock A; Eriksson BI
    Thromb Haemost; 2002 Apr; 87(4):580-5. PubMed ID: 12008938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy.
    Secin FP; Jiborn T; Bjartell AS; Fournier G; Salomon L; Abbou CC; Haber GP; Gill IS; Crocitto LE; Nelson RA; Cansino Alcaide JR; Martínez-Piñeiro L; Cohen MS; Tuerk I; Schulman C; Gianduzzo T; Eden C; Baumgartner R; Smith JA; Entezari K; van Velthoven R; Janetschek G; Serio AM; Vickers AJ; Touijer K; Guillonneau B
    Eur Urol; 2008 Jan; 53(1):134-45. PubMed ID: 17597288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inpatient and outpatient occurrence of deep vein thrombosis and pulmonary embolism and thromboprophylaxis following selected at-risk surgeries.
    Amin AN; Lin J; Thompson S; Wiederkehr D
    Ann Pharmacother; 2011 Sep; 45(9):1045-52. PubMed ID: 21862717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol.
    Beksaç B; González Della Valle A; Anderson J; Sharrock NE; Sculco TP; Salvato EA
    Clin Orthop Relat Res; 2007 Oct; 463():114-9. PubMed ID: 17960674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
    Ennis RS
    J South Orthop Assoc; 2003; 12(1):10-7. PubMed ID: 12735619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence and prevention of symptomatic thromboembolic disease following unicompartmental knee arthroplasty.
    Lombardi AV; Berend KR; Tucker TL
    Orthopedics; 2007 May; 30(5 Suppl):46-8. PubMed ID: 17549868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial.
    Kaye ID; Patel DN; Strauss EJ; Alaia MJ; Garofolo G; Martinez A; Jazrawi LM
    Bull Hosp Jt Dis (2013); 2015 Dec; 73(4):243-8. PubMed ID: 26630467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burden of illness in venous thromboembolism in critical care: a multicenter observational study.
    Patel R; Cook DJ; Meade MO; Griffith LE; Mehta G; Rocker GM; Marshall JC; Hodder R; Martin CM; Heyland DK; Peters S; Muscedere J; Soth M; Campbell N; Guyatt GH; ;
    J Crit Care; 2005 Dec; 20(4):341-7. PubMed ID: 16310605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.